ABSTRACT:
In an eight-week study, we contrasted losartan and valsartan, two angiotensin II receptor antagonists, as antihypertensive medications. A placebo, Adults with simple essential hypertension (baseline seated diastolic blood pressure < 115 mm Hg and > 95 mm Hg) were randomized to receive either 50 mg losartan or 80 mg valsartan once daily. The dosages of both the active drug and the placebo were doubled after four weeks. Systolic and diastolic blood pressure readings were taken while the patient was seated, and the response rate was assessed. The side effects (AEs) that are most frequently reported were headache, nausea/vomiting, dizziness, and malaise/fatigue; nonetheless, their frequency is comparable to that of placebo. Arguments are presented to readers indicating that a dosage of 50 mg of losartan is likely too low and that a daily dose of 100 mg or more is preferable. Valsartan has been demonstrated proven be safe and well tolerated in both single and combination treatment for hypertension in a variety of populations, such as children, the elderly, diabetics, obese individuals, and those with a higher risk of cardiovascular disease. Despite the necessity for closer monitoring of serum potassium levels, valsartan is safe and well tolerated in individuals with nephropathy. In this study, valsartan (80/160 mg) monotherapy was as effective and well tolerated as 50/100 mg losartan in the treatment of mild to moderate essential hypertension. Compared to 100 mg losartan, it has a much higher responder rate at 160 mg.